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Abstract
Regulatory T cells (Treg) are critical for preventing autoimmunity and
curtailing responses of conventional effector T cells (Tconv). The
reprogramming of T-cell fate and function to generate Treg requires
switching on and off of key gene regulatory networks, which may be
initiated by a subtle shift in expression levels of specific genes. This
can be achieved by intermediary regulatory processes that include
microRNA and long noncoding RNA-based regulation of gene
expression. There are well-documented microRNA profiles in Treg
and Tconv, and these can operate to either reinforce or reduce
expression of a specific set of target genes, including FOXP3 itself.
This type of feedforward/feedback regulatory loop is normally stable
in the steady state, but can alter in response to local cues or genetic
risk. This may go some way to explaining T-cell plasticity. In addition,
in chronic inflammation or autoimmunity, altered Treg/Tconv
function may be influenced by changes in enhancer–promoter
interactions, which are highly cell type-specific. These interactions are
impacted by genetic risk based on genome-wide association studies
and may cause subtle alterations to the gene regulatory networks
controlled by or controlling FOXP3 and its target genes. Recent
insights into the 3D organisation of chromatin and the mapping of
noncoding regulatory regions to the genes they control are shedding
new light on the direct impact of genetic risk on T-cell function and
susceptibility to inflammatory and autoimmune conditions.
Keywords: gene regulation, genetic risk of disease, microRNA,
T-cell fate, T-cell plasticity, Treg FOXP3.
INTRODUCTION: THE TREG PHENOTYPE
A healthy immune system must balance robust
reactivity towards pathogens with limited
reactivity, or tolerance, to self-antigens, commensal
bacteria and food/environmental antigens.1 The
effector arm of the adaptive immune system
comprises CD8 and CD4 cells, defined by their
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function and ability to respond to antigens
presented on either MHC class 1 or 2, respectively.
Within the CD4+ T-cell compartment, there are
specific effector subsets that are capable of
responding to defined antigens in specific
locations, and antigen specificity is determined by
the TCR repertoire. This TCR repertoire is generated
during CD4+ commitment and differentiation in
the thymus in a process that includes deletion of
(strongly) self-reactive TCR bearing T cells. Despite
this, there is the possibility of self-reactive T cells
being released into the periphery. To manage this,
special subsets of CD4+ T cells called regulatory T
cells (Treg) are also generated, both in the thymus
and in the periphery. While both natural thymic
Treg or nTreg, and induced or peripheral Treg are
similar in function, they have different origins and
roles in regulating other immune cells.2,3 In a
general sense, Treg act as ‘policemen’ of the
immune system to limit rogue immune activity, and
this role in immune homeostasis is critical. In
addition to regulating antigen-specific immune
responses, Treg are capable of regulating cell
function in an antigen-independent manner.4
Treg play a central role in immune regulation by
actively controlling the proliferation and activation
of cells of both the adaptive and innate immune
systems using multiple mechanisms.1 Treg use
multiple suppressor mechanisms, and the mechanism
is likely to differ according to the physiological and
inflammatory states encountered.1,5 Failure of
tolerance can lead to autoimmunity and chronic
inflammation, and the loss of tolerance can be
caused by defects in Treg function or insufficient
Treg numbers, or by unresponsive or overactivated
effector cells.
The regulatory T-cell first gained widespread
recognition as a T-cell lineage upon the
demonstration by Sakaguchi et al.6 that stable
expression of the IL2 receptor (CD25) tracks with
suppressor function in CD4+ T cells. Many groups
have since investigated this lineage, and it is now
clear that while CD25 expression is strongly
upregulated on Treg, it is also a transient activation
marker for CD4+ T-cells without regulatory
function, so is not an exclusive Treg marker. The
second major discovery in this field was that the
Treg lineage is dependent on the expression of the
transcription factor FOXP3, which controls a gene
regulatory network essential for suppressor
function. A third significant discovery was the
existence of two Treg populations of different
origin: natural or thymic Treg emerge from the
thymus fully mature and stably expressing FOXP3.
In contrast, peripheral or induced Treg arise from
na€ıve T-cells which do not express FOXP3 until
stimulated in the presence of cytokines and
transcriptional activators which turn on the FOXP3
gene. This reveals the ability of the immune system
to acquire tolerance to antigens from both
inherited repertoires (thymic Treg) and to de novo
antigen exposure, such as commensal bacteria,
food, chemical compounds and alloantigens in
pregnancy (induced Treg). More recently, a search
for cell surface surrogates of FOXP3 (FOXP3 cannot
be used to isolate viable Treg as it requires
intracellular staining) has revealed that reduced
expression of the IL7 receptor (CD127) is also a
hallmark of the human Treg phenotype.7,8 It has
been reported that CD127 is not selective for
mouse Treg, as activated murine Treg express
CD127 strongly.9 The differential expression of
cytokine receptors on Treg may be important in
restricting survival or function as, for example,
mature human Treg are dependent on exogenous
IL2, but not on IL7. This also allows for the
possibility that the expression of a specific cytokine
receptor on Treg may enable them to act as a
biological sink to sequester cytokine in a tissue
microenvironment.10
Regulatory T cells are dependent on the
expression of FOXP3 for both their formation and
function, and FOXP3 controls a gene regulatory
network essential for suppressor function. Each
lineage in the helper arm of the CD4 pool has a
defining transcription factor, and it is the
expression of this transcription factor that shapes
function. T-cell transcription factors can be
induced by specific external stimuli, and as a
result, a transcriptional programme is established
which enables the cell to express pathogen-
specific effector molecules. This raises the
possibility that function may not be
predetermined and fixed in a given lineage, but is
plastic. The need for plasticity in T-cell responses
may be twofold; it may be part of a mechanism to
quell the active immune response once the
pathogen has been cleared. In contrast, functional
plasticity may enable tailored responses which are
tuned to the challenge type and site. A logical
consequence is that different defects in a Treg
may be implicated in different autoimmune and
inflammatory disease settings.
It is now clear that much complexity in the Treg
phenotype exists than originally appreciated, and
a growing number of other cell surface markers
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are found on specific Treg subsets, for example
TIGIT,11,12 GARP,13–16 CD73 and CD39.17,18 These
markers are frequently also found on effector cell
populations, and an emerging theme is that
either Treg are able to transition between
functional states or that the Treg compartment is
paired with the Tconv effector compartment so
that any immune response mediated by a T-cell
can be controlled by a matching Treg.19 This is
supported by the detection of lineage-specific
transcription factors (e.g. Tbet,20 IRF421) being co-
expressed with FOXP3 in Treg subsets, using
various mouse models, but this has yet to be
confirmed in humans. It is possible that the
balance of Treg to effector lineages may be
altered under specific circumstances or that the
Treg themselves may switch fates. As more
signature molecules for each functional subset are
confirmed, and highly purified cell populations
are subjected to expression profiling and
functional assay, the question of altered
committed lineage proportions vs plasticity will be
better understood.
TREG AND DISEASE
Decreased Treg numbers or impaired function in
adult mice leads to autoimmune diseases.1
Adoptive transfer of Treg ameliorates many
diseases, including the nonobese diabetic (NOD)
and inflammatory bowel disease mouse models,1
as well as mouse models of pregnancy disorders
which mimic autoimmune disease in many
regards.22 These studies strongly indicate that a
threshold of Treg function is required throughout
life to restrain autoreactive T cells and/or
inflammatory responses, and this prevents
autoimmune disease onset. The early
development of autoimmune disease in IPEX
patients, who lack FOXP3 and Treg,23 confirms
that Treg are also essential in humans.24
Functional defects in Treg in type 1 diabetes and
inflammatory bowel disease have been
reported,25,26 but there are conflicting reports in
the literature about reduced Treg numbers in
autoimmune cohorts. These conflicts arise in part
because of methods for enumerating Treg, the
need to consider the amount of FOXP3, as well as
the absolute presence or absence of staining for
FOXP3 in flow cytometric data, and the impact of
activation and source of sample on analysis.
There are likely to be many points in relevant
gene regulatory networks that alter Treg or Tconv
function, if affected by genetic or environmental
risk factors. It is relatively rare to find mutations in
FOXP3 itself, so many Treg-specific defects in
autoimmune disease are likely to result from
reduced FOXP3 function or alterations in
expression of downstream targets. There are also
genes involved in Treg function that are FOXP3-
independent. Type 1 diabetes is an example of a
disease which arises as a result of complex
interactions between genetic and environmental
factors conspiring to drive disease progression. A
meta-analysis of six genome-wide association
studies to identify single nucleotide polymorphisms
that track with type 1 diabetes identified 45 loci,27
and using our FOXP3 ChIP data,28 we observed that
34 (75%) contain a FOXP3 binding site. A more
recent fine mapping of genetic risk of type 1
diabetes identified 51 distinct loci, of which 34
mapped to a gene.29 Using the filter that a gene is
a potential target of FOXP3 if there is a FOXP3
binding site within 20Kb of the transcription start
site, 37 (72%) of these loci are putative targets of
FOXP3. This suggests the potential for there to be a
Treg-specific defect directly as a result of
polymorphism in these genes or their regulatory
elements, but the functional link between them is
currently unknown. While many cell types
contribute to immune homeostasis, Treg/Tconv
defects play a major role in the pathology of
human autoimmune disease, and epigenetic
profiling is now providing compelling evidence
that much of the autoimmune disease-associated
risk impacts Treg- and Tconv-specific transcriptional
programmes. This suggests that susceptibility to
disease is causally linked to either Treg plasticity,
altered Treg development or altered Treg function,
and for example, a Treg defect which is responsive
to TNF antagonism has been demonstrated in
rheumatoid arthritis.30
TRANSCRIPTIONAL CONTROL OF TREG
FORMATION AND FUNCTION
Since its identification as the key transcription
factor for the formation and function of Treg in
mouse and humans,23,31,32 FOXP3 has been the
subject of much investigation. Molecular
mechanisms for the action of FOXP3 in shaping
regulatory T cells and their critical role in
maintaining lifelong tolerance are now being
better understood. It is increasingly clear that loss
of function is implicated in a wide variety of
autoimmune and chronic inflammation settings;
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however, there remains the possibility that loss of
function is a consequence rather than the cause
of autoimmunity and chronic inflammation. High-
resolution functional genomics using genotyped
patient samples, when combined with mouse
models, will undoubtedly resolve this.
Important insights into the transcriptional
control by FOXP3 have been defined by chromatin
immunoprecipitation (ChIP) experiments, which
trap transcription factors bound to DNA. Studies
carried out in mouse Treg33 and in human
Treg28,34 have defined the target regions in
chromatin bound by FOXP3. As well as identifying
a significant number of loci both directly bound
by FOXP3 and associated with differentially
expressed genes in Treg, many loci were identified
that are either too far from a transcription start
site to annotate to a target gene easily, or do not
appear to be associated with differentially
expressed genes in Treg. For example, in our
human FOXP3 ChIP data set, of almost 3000
FOXP3-bound regions, only 750 were also
annotated to genes differentially expressed in
human Treg28 (Figure 1). This has revealed a core
network of genes that are tightly regulated by
FOXP3 and has also identified significant
bioinformatic limitations in annotation of FOXP3-
bound regions. It is now clear that noncoding
regulatory regions are critical for T-cell-specific
gene regulation, may be far from their target
gene and that they can exert their function via
DNA looping.35 This DNA looping brings specific
genes and regulatory elements together into
transcriptionally active hubs36 and this may be
different in Tconv or Treg. However, since DNA
looping cannot currently easily be predicted using
bioinformatics approaches, proximity-based
annotation of FOXP3 targets based on linear DNA
organisation under-ascribes transcriptional targets
to FOXP3 binding sites in chromatin. Hence,
alterations to the binding of FOXP3 to its target
genes may contribute to plasticity or lineage
commitment and function.
FOXP3 EPIGENETIC REGULATION
FOXP3 is itself subject to tight regulation, and this is
both at the level of transcription and post-
transcription. The modifiable mediators of this
regulation include methylation,37–44 acetylation45–47
and microRNA-mediated control of transcript
translation.28,48–55 The global regulation of FOXP3 is
influenced by chromatin organises, including SATB1
acts both during development and in mature
cells.48,58 The regulation of FOXP3 by distinct
modules including the Treg-specific demethylated
region (TSDR)37,38,59 has revealed marks for FOXP3
expression control and can discriminate between
thymic Treg FOXP3 expression and activation-
dependent expression of FOXP3 in naive T cells in
the periphery37,43 (gene annotation and species
conservation depicted in Figure 2). The methylation
or demethylation of the TSDR is controlled by DMT3
or TET, respectively, and the regulation of this
process is associated with thymic induction of FOXP3
as well as induction of FOXP3 in the periphery.60–62
Additional analysis of the regulatory elements in the
FOXP3 locus has defined specific regions near to the
TSDR named conserved noncoding sequence (CNS)
1, 2 and 3.63 CNS1 is responsible for expression of
FOXP3 specifically in iTreg. CNS2 contains the TSDR
and is responsible for maintenance of FOXP3 in all
dividing Treg and CNS3 is the pioneer site for FOXP3
expression in thymic origin nTreg.63 Occupancy by
specific transcription factors at each of these loci is
now characterised, and this includes AP1 and NFAT
at CNS1,59 Runx1 and CBFb at CNS264 and cREl at
CNS3.63 The observation that na€ıve human CD4+ T
cells induce FOXP3 upon activation,65–67 and that in
the presence of TGFb and all-trans retinoic acid
(ATRA)63 the expression of FOXP3 is stabilised to
some degree, was defined transcriptionally by the
finding that the activation-induced expression of
FOXP3 results from partial but not complete
demethylation of the FOXP3 locus in iTreg.37 This
suggests that the relative methylation state of the
Figure 1. Functional annotation of FOXP3-bound mRNA regions of
the human genome intersected with differential mRNA expression
(left Venn diagram), and FOXP3-bound microRNA regions of the
human genome intersected with differential miR expression (right
Venn diagram), showing that a subset of mRNAs and miRs are both
differentially expressed and FOXP3 targets.
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FOXP3 regulatory elements encoded by CNS1, 2 and
3 are an axis for Treg plasticity. In addition to gain of
FOXP3, there is also the consequence of loss of
FOXP3 on Treg function due to exhaustion or
chronic overstimulation, which might occur during a
potent immune response. This has led to the concept
of the ex-Treg. Fate mapping studies in mice
elegantly demonstrate that Treg can lose expression
of FOXP3, but are of thymic Treg origin based on
genetic marking. These studies link ex-Treg to
susceptibility to multiple sclerosis68 and RA,69 and
suggest that high levels of IL6 can induce this loss of
FOXP3 expression in vivo. A contributing factor may
be reduced IL2 signalling, which is in part mediated
by SOCS1.70 Hence, a second axis on plasticity may be
the impact of local pro-inflammatory cytokines
including IL-6.
TISSUE AND METABOLIC CUES CAN
ALTER TRANSCRIPTIONAL
PROGRAMMING OF T CELLS
The recruitment of effector cells to sites of
infection is driven by local tissue cues as well as
pathogen signals, and the pro-inflammatory
milieu at these sites may contribute to the
shaping of the phenotype of the cells once they
arrive.19,71 It is now emerging that in addition
to these classic cytokine/cytokine receptor-
mediated signals, T cells are also highly
responsive to other metabolic cues, and these
are also sensed by surface receptors and
biochemical pathways.
There are a wide range of molecules that can
be detected via cell surface receptors or
transporters, and these include sugars, amino
acids, energy molecules, vitamin metabolites and
food metabolites from the microbiome, as well as
oxygen tension and environmental toxins.72 Well-
characterised sensors of metabolic stimuli include
mTor and HIF,73,74 which can influence the
differentiation of Treg vs effector T-cells including
Th17. These exert a network effect as they in turn
regulate gene networks influencing biochemical
responses including glycolysis. The balance of
oxidative phosphorylation is linked to FOXP3
expression and regulatory phenotype,75,76 and this
in part enables Treg to function in environments
that are under oxidative stress.77
Metabolites which can alter transcriptional
programming have also been identified. The role
of the vitamin A metabolite retinoic acid ATRA
has been well characterised in the context of T-
cell differentiation, and it is evident that either
alone or in combination with other factors ATRA
can induce either induce Treg or Th17 phenotypes
by upregulating FOXP3 expression or ROR gamma
expression, respectively.78 This axis can also be
influenced by sensing toxins and pollutants via
the aryl hydrocarbon receptor (AHR).79,80
Induction of FOXP3 in response to food
metabolites including short-chain fatty acids is
now well characterised at the molecular levels and
is particularly relevant for induced Treg
generation in the gut. Butyrate generated by
commensals in the colon is able to activate the
FOXP3 locus and promote a tolerogenic bias.81,82
These mediators play a key role in differentiation
of na€ıve T cells, but it is less clear whether they
drive fate change in committed T-cell subsets.
Nonetheless, all of these pathways and inducer
molecules are implicated in altered Treg function
Figure 2. (a) Schematic representation of the human FOXP3 gene, annotating the three conserved noncoding sequences involved in regulating
gene expression (CNS1, 2, 3). (b) A VISTA alignment of mouse and human FOXP3 showing regulatory regions which are conserved between
species in red, conserved untranslated regions in light blue and conserved exons in lilac.
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or numbers in disease, and are the targets for
interventions to restore balance.
TISSUE AND METABOLIC CUES CAN
ALTER TREG FUNCTION
Given that the Treg have to home to the same
locations to regulate the effector response after
pathogen has been cleared, they are also exposed
to the same environment. The gene regulatory
network controlled by FOXP3 has to be robust
enough to resist this environment, and this is
achieved by the combination of repression of
expression of key inflammatory cytokine
receptors, rendering the Treg unresponsive, and
induction of key suppressor genes. However, it is
also possible that these tissue-specific cues can
shape Treg function and limit their potency to
enable pathogen clearance. Given that activation
can induce FOXP3 in effector cells, this may also
be the mechanism by which the effector cells




The regulatory network of genes controlled by
FOXP3 is essential for the Treg phenotype. Of
the 2000-3000 target genes identified by FOXP3
ChIP,28,83 a subset are directly differentially
expressed or repressed in Treg at any given time,
including SATB148 (Figure 1). These genes
combine with FOXP3 to form the FOXP3 gene
regulatory network and shape the function of
Treg. It is important to note that there are also a
number of differentially expressed genes in Treg
that are either indirect targets of FOXP3 or are
downstream of FOXP3 direct regulation, but
which may be controlled by FOXP3-induced miRs.
Transcriptomics analysis reveals that microRNAs
(miRs) are both direct and indirect FOXP3 targets
in Treg, suggesting a key role for miRs in Treg
function. MicroRNAs (miRNAs) are 21-22nt,
noncoding RNAs commonly found in the introns
of protein-coding genes. Their primary function
is to post-transcriptionally regulate gene
expression by binding to a complementary target
sequence, typically found in the 30 or 50 UTR of a
gene. Depending on the affinity, this interaction
leads to cleavage of the mRNA transcript or
inhibition of translation. A single miRNA has the
ability to target and regulate multiple genes.
Likewise, multiple miRNAs are able to target a
single mRNA transcript, which gives rise to
complex regulatory networks and fine-tuning of
regulation.
A key discovery demonstrating that miRNA are
critical to T-cell function was revealed by
conditional null mutation in Dicer or Drosha. Cobb
et al. selectively inactivated miRNA formation in
Treg at a late stage in T-cell development.49 This
induced a fatal inflammatory disease in mice due
to a significant reduction in Treg.49 Liston et al.
also showed that miRNAs are crucial to Treg
suppressive function. In comparison with their
healthy counterparts, the Dicer knockout mice
showed significantly reduced suppressive
function.51 Under similar conditions, Zhou et al.
demonstrated that depletion of mature miRNAs
leads to uncontrolled autoimmunity and skewing
of iTreg to a Th1/Th2-like effector phenotype, such
that iTreg exhibited altered surface markers and
cytokine expression profile. Interestingly, no effect
was seen in tTreg.55
FOXP3 COOPERATES WITH
MICRORNAS VIA REGULATORY LOOPS
WHICH TIGHTLY CONTROL THE FOXP3
TRANSCRIPTOME
These results suggest that miRNAs are critical in
the development and function of Tregs and that
miRNAs may confer a rheostat-like function in
T-cell lineage differentiation and plasticity.
Therefore, there is interest in the cooperation of
miRNAs and FOXP3 and how they may control
Treg phenotype and function. Genome-wide
molecular approaches are being utilised to
identify the key genes and gene regulation
interactions in human Treg, including ChIP, iCLIP
and expression profiling, and this aides
understanding Treg function and stability. We
have previously demonstrated that miRNAs, such
as miR-155, and FOXP3 cooperate to coordinately
regulate other key genes in Treg, including
SATB148 and ZEB228 (Figure 3), and have
identified a number of other candidate miRNAs
involved in the Treg genotype. It is interesting to
observe that a common miRNA/FOXP3-mediated
molecular switch is able to regulate several key
genes, which forms a core part of the FOXP3 gene
regulatory network (GRN).
MicroRNAs are hence implicated as key
regulators of Treg function. A differential miRNA
signature for human nTreg comprising positively
2018 | Vol. 7 | e1011
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regulated miRNAs includes miR-21, 155, 125a,
146a, 181c and 374. These miRNAs form part of
the network of feedforward regulators in Treg
(Figure 4). However, less is known about the
miRNAs which form part of a negative regulatory
loop. Recent analysis reveals a miR-31 target
sequence in the 30 UTR of FOXP3, suggesting that
miR-31 may be able to negatively regulate FOXP3.
Lentiviral expression of miR-31 in cord blood-
isolated nTreg showed a significant reduction in
FOXP3, measured by quantitative RT-PCR.
Likewise, antagonism of miR-31 expression leads
to increased expression of FOXP3, suggesting that
miR-31 regulates FOXP3. A luciferase reporter
assay was performed in HEK293 and HeLa to
determine whether this regulation was by direct,
rather than indirect targeting. The results suggest
that FOXP3 is a direct target of miR-31.53
MicroRNA-31 was not identified in the mouse
miRNA Treg signature.49 However, in mouse
Zhang et al. identified a potential FOXP3 binding
site within the promoter region of the gene
encoding murine miR-31,84 suggesting FOXP3
itself may directly target miR-31. Analysis of
miRNA expression by qRT-PCR revealed miR-31
was approximately 90-fold higher in CD4+FOXP3-
cells in comparison with CD4+FOXP3+ (Treg) cells.
Furthermore, a FOXP3 ChIP assay performed in
mouse Treg showed significant recruitment of
FOXP3 to the miR-31 promoter.9 Combined, these
experiments suggest that FOXP3 binds and
downregulates miR-31 expression in mouse Treg,
and alignment with the human miR-31 host gene
suggests that there is also a FOXP3 consensus
region in the human miR-31 locus.
Given the potential relationship between FOXP3
and miR-31 (Figure 5), it is unsurprising to find
that miR-31 is dysregulated in several
autoimmune diseases such as IBD or Crohn’s
disease85,86 and Kawasaki disease.87 Therefore,
understanding the molecular mechanisms by
which FOXP3 and miR-31 regulate each other, and
identifying the target genes within this regulatory
network, could contribute to the development of
novel treatments for autoimmune disease.
The combined impact of the sentinel
transcription factors in each lineage and the
miRNAs controlled by them shapes CD4+ T-cell
phenotypes. As modelled in Figure 6, the
commitment to the Treg lineage is dependent on
FOXP3 and a set of miRNAs controlled by it. In
Figure 3. FOXP3- and FOXP3-induced microRNAs (green) cooperate
to tightly repress (red) target genes in Treg, to reinforce the





Figure 4. Molecular model of the FOXP3 gene regulatory network feedforward loops. FOXP3 represses key effector function genes both by
direct binding to regulatory elements associated with the gene (e.g. SATB1) and by inducing miRs that themselves target the same gene 30 UTR.
In addition, FOXP3 induces Treg functional genes to reinforce the Treg lineage and phenotype, while suppressing inducers of effector lineage
commitment.
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effector cells such as Th17 cells, an opposing
transcription factor orchestrates the gene
regulatory network, and external signals can
influence the expression of these.88 This may
enable switching between functional phenotypes
by enabling one transcription factor to decline
and another to dominate, which is a potential
molecular mechanism for plasticity. In addition, it
is interesting to speculate that the transient
expression of FOXP3 in activated conventional T
cells then induces miRs which repress effector
function gene networks, and this enables the
effector cells to return to a resting state
(Figure 7). These models require further
evaluation in human cells.
LONG NONCODING RNAS AND TREG
In addition to short noncoding RNAs such as miRs,
an emerging theme from high-resolution
Figure 5. Molecular model of the FOXP3 gene regulatory network feedback loop controlling FOXP3 expression. In a stable Treg, FOXP3
represses miR31 by direct binding to regulatory elements associated with the gene, and in stable effector T cells, miR31 expression prevents the
expression of FOXP3 by targeting FOXP3 mRNA for degradation. Subtle alterations in levels of either miR31 or FOXP3 will have reciprocal effects
on the expression of each, providing a threshold for transition between FOXP3 +ve and ve states.
Figure 6. Integrated model of the plasticity of phenotypes based on molecular switching driven by induction of miRs which regulate the sentinel
transcription factor for one phenotype and allow expression of the transcription factor driving the other phenotype. In regulatory T cells, a suite
of FOXP3-induced miRs are expressed in the steady state, but as a result of external cues such as cytokine signalling, these miRs are reduced, and
competing miRs including miR31 are increased, reducing FOXP3 expression and releasing other transcription factors from repression, facilitating a
transition and reversible functional switching.
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functional annotation of the human and mouse
genomes is the prevalence and importance of
long noncoding RNAs (lncRNAs) as subtle
regulators of gene expression. These are
transcripts of greater than 200bp that are not
translated, but that can interact with mRNA and
chromatin to regulate gene expression. There is a
evidence that they function either as stabilisers of
DNA looping to form transcriptional hubs and as
part of the RNA binding protein complex to
regulate transcription.89 In addition to a role in
shaping the development of many tissues and
cells, there is a defined role for lncRNAs in
differentiation of T-cell subsets.90 Evidence of the
impact of long noncoding RNAs in immune
function is becoming clear,91,92 and alterations in
function can be identified in autoimmune and
chronic inflammation samples which are linked to
lncRNAs.93 The importance of lncRNA in Treg has
been elegantly demonstrated for a lncRNA (Flicr)
which subtly controls the expression of FOXP3 in
mouse and human Treg.94 Interestingly, the
impact of Flicr on FOXP3 expression is via
interactions with conserved noncoding elements
and loss of Flickr results in reduced expression of
FOXP3. This may be the prerequisite for
transcriptional reprogramming of Treg under
external cues such as from reduced IL2 signalling,
reinforcing the model that plasticity can be
induced by relatively small changes in
transcriptional networks. It is interesting that
lncRNA plays a role in stabilising DNA looping and
is often encoded within enhancer regions, which
shape the expression of multiple genes. The
observation that autoimmune genetic risk is
found in enhancers and the enhancers loop to
form the regulatory hubs on key immune function
genes suggests that there could be a complex
network effect on multiple targets from genetic
risk at a single lnc/enhancer module.95
GENETIC RISK OF AUTOIMMUNE
DISEASE ALTERS TREG FUNCTION
Genome-wide mapping of epigenetic variation in
Treg and conventional T-cells reveals cell type-
specific transcriptional activity,83,96 and large-
scale cataloguing of the marks associated with
active, open or closed chromatin has opened the
way for understanding cell type-specific gene
regulation (e.g. epigenomics roadmap,97,98
FANTOM99–102). In the post-GWAS era, there are
very strong data linking genetic variation (single
nucleotide polymorphism or snp) in a wide
variety of immunological disease cohorts, but
identification of individual causal target genes
has been difficult, as it is now apparent that
the majority of this genetic variation does not
disrupt the coding region of genes, but is
located in noncoding regions.103 Numerous
independent approaches combining these
genotyping data with the functional annotation
of the human genome indicate that the majority
of this noncoding genetic variation overlaps,
and thus likely influences, transcriptional
regulatory elements and long noncoding RNAs
(lncRNAs).104–106
In the case of autoimmune diseases data sets,
there is also significant enrichment of genetic
variation in T-cell-specific regulatory elements,
including promoters and enhancers,106,107
suggesting that dysregulation of multiple separate
pathways in the immune system can result in the
same phenotype from unrelated genotypes. In the
case of type 1 diabetes, a recent Bayesian analysis
of the intersection between genetic risk and
regulatory motifs found significant enrichment of
snps within enhancer regions,29 suggesting that
the consequence of single nucleotide
polymorphism may be to alter the expression of
multiple target genes. This is inferred from the
observation that genetic risk alters the function of
regulatory elements, and the targets of those
regulatory elements are dependent on either
short- or long-range DNA looping in many cases.
While bioinformatics is powerful in identifying
enrichment of sequence motifs, and this can be
combined with other data such as transcription
factor binding sites, epigenetic modifications and
genetic variation, it does not yet have the ability
to efficiently predict the targets of regulatory
regions. This is partly because the conformational
networks formed in any cell are exquisitely cell




Activated T cell, for example
responding to infection Effector function
reduced, for example
infection cleared
Figure 7. Integrated model of regulation of effector function in
effector T cells based on molecular switching driven by transient
repression of miR(s) which de-represses FOXP3, therefore transiently
repressing effector function genes. This enables shut down of an
immune response upon clearance of the pathogen.
ª 2018 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australasian Society for Immunology Inc.
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on the expression of cell type-restricted
transcription factors such as FOXP3.
ENHANCER–PROMOTER INTERACTIONS
SHAPE THE FUNCTION OF TREG
Gene coding regions comprise as little as 1.5% of
the human genome, encoding approximately
21 000 genes. Genome-wide functional annotation
endeavours including ENCODE, FANTOM and the
Roadmap have enabled a far deeper understanding
of the architecture of the human genome, and it
has become clear that interactions between coding
and noncoding elements are essential for normal
gene regulation and maintenance of stable
phenotype. This suggests that the much of the
genome is involved in controlling the expression of
those protein-coding genes.
Chromatin structure is known to have a major
influence on gene expression by controlling
transcription factor access to binding sites in
enhancers and promoters.108 Localised patterns of
chromatin modification, such as DNA methylation,
histone modification and nucleosome
remodelling, correlate with enhancer activity,
transcription factor binding and initiation or
repression of transcription.99,109,110 More recently,
these approaches have enabled the identification
of a rare subset of enhancers, termed
super-enhancers.103,107 Super-enhancers are
characterised by a relative enrichment of active
enhancer-associated epigenetic marks and
transcriptional cofactor binding, and they appear
to regulate key genes involved in cell type-specific
function.103,107
Determining the genes that enhancers control
will complete the picture of Treg gene regulation.
DNA looping plays a critical role in transcriptional
regulation by allowing widely separated enhancers
to interact with promoters at gene hubs.111,112
Hence, DNA looping facilitates gene network
formation as a single enhancer may interact with
more than one promoter, and a single promoter
may be contacted by more than one enhancer.
Many of these interactions occur in a tissue-specific
manner and appear to be the major determinants
of cell type-specific responses.111,113–115 Critically,
many enhancers do not interact with the nearest
active gene but contact gene promoters many
hundreds to thousands of kilobases away through
long-range DNA looping (modelled for T cells in
Figure 8).111,112
These findings highlight the difficulty in
annotating regulatory regions to specific target
genes using ChIP and chromatin accessibility data
alone. Likewise, while genome-wide association
studies have identified potential disease-
associated variation in regulatory regions, the
genes they affect remain largely unknown116
(mutation impact modelled in Figure 9). FOXP3
itself may actively drive intrachromosomal
interactions in Treg. Structural data indicate
Figure 8. Conformation-dependent interactions contribute to gene regulation networks, and these are not readily predicted by bioinformatics
approaches. (a) Linear annotation of TF binding site data to nearest neighbour is only accurate if within a short distance from the TSS.
(b) unidentified FOXP3 binding sites, and distal regulatory interactions are annotated after incorporation of DNA looping data from conformation
capture experiments.
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FOXP3 multimers can bind widely separate
recognition sites, as demonstrated by 4C assay of
the Ptpn22 locus following FOXP3 overexpression
in murine Tconv.34 New approaches combining
chromatin state profiles, transcription factor
binding and autoimmune disease loci with
enhancer–promoter contact maps generated by
chromosome conformation capture are beginning
to unravel the functional consequences of disease-
associated noncoding DNA variation.
MAPPING THE 3D GENOME
Chromosome conformation capture (3C) assays are
now the method of choice to study the role of
DNA looping in transcriptional regulation. These
assays directly identify genomic loci that are in
sufficiently close proximity in living cells to be
cross-linked.117 Several versions of 3C such as 4Cseq,
ChIA-PET,112 5C111 HiChIP118 and Hi-C113 allow for
mapping of chromatin interactions on a whole
genome level. Recently, to improve the resolution
and sensitivity of Hi-C assays, in situ protocols have
been developed. In addition, for focussed
interaction mapping oligonucleotide capture
technology has been used to enrich for regions of
interest (such as promoters) in the Hi-C library prior
to high-throughput sequencing119–121 or chromatin
immunoprecipitation combined with Hi-C to
interrogate individual protein-centric confor-
mation maps122 The use of oligo-capture
technology significantly improves sensitivity and
resolution without the associated increase in
sequencing costs required for high-resolution
analysis of traditional Hi-C libraries.113 Importantly,
Chromosome conformation capture-based assays
have been used to successfully identify targets of
disease-associated variation in other cell
types111,112,120,123 including human CD4 and CD8
populations,124 and data from a genome-wide
H3K27ac Hi CHIP (acetylated histone CHIP and
conformation capture) performed in na€ıve T cells,
Th17 and Treg, have annotated accessible
chromatin interacting with regulatory elements,125
shedding new light on the lineage-specific
interactome in these cells. However, intersection
with FOXP3 binding site data, genetic risk and




There are complex dynamic regulatory processes
controlling Treg generation and stability that
involve microRNA and long noncoding RNA-based
regulation of gene expression. These interact with
transcription factors which themselves define
function. In addition, enhancers and super-
enhancers establish the level of gene expression
and response to T-cell activation. This gives three
layers of reinforcement of Treg phenotype, and
each may be a point of disruption in either disease,
altering the functional Treg pool, or in response to
tissue and inflammatory cues, altering fate. It is
evident that in the steady state, FOXP3 establishes
and maintains a strong regulatory phenotype, and
this is resistant to reprogramming; however, under
specific circumstances this can be changed, and this
either results in formation of so-called ex-Treg, or
in a cell with effector-like function that expresses
less or no FOXP3. The definition of the process as
either plasticity or exhaustion is hard to define in
man. By combining genomics and high-resolution
cell phenotyping, followed by functional validation
by methods including gene editing, the answer to
the question of mechanisms underpinning
plasticity in human Treg will likely soon be
(a) (b) (c)
Figure 9. Functional annotation of genetic risk from the GWAS data set which maps to FOXP3 ChIP binding regions. The addition of chromatin
conformation data allows identification of the target genes, and this enables analysis of the impact of genetic variation. In a Tconv, the gene is
expressed because there is no FOXP3 (a). In a normal Treg, the gene is repressed (b), but in a Treg from the disease cohort, the sequence
variation results in loss of a FOXP3 binding site, as a result the target gene is no longer repressed (c). The functional impact is at a distal
regulatory element, not in the target gene itself.
ª 2018 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australasian Society for Immunology Inc.
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provided. There is no doubt that microRNAs have
the capacity to tune the alterations in genotype
required to alter phenotype, and perhaps these are
the rheostat of fate. New insights into the
contribution of genetic risk to gene expression in
Treg in diseases including autoimmunity will also
reveal whether dysregulation of microRNAs is a
tipping point for altered phenotype. While elegant
mouse models provide mechanistic insights and
have considerable power, for example in fate
mapping of Treg subsets, there is still a need to
demonstrate the plasticity or paired generation of
Treg subsets in man.
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